Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $1.7 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 81.75% year-over-year to $1.7 billion in Q1 2026; TTM through Mar 2026 was $5.6 billion, a 50.24% increase from a year earlier, with the FY2025 full-year figure at $1.7 billion, up 78.2% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.7 billion, down from $1.7 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for KYMR reached as high as $1.7 billion in Q4 2025 and fell as low as $523.4 million in Q2 2022.
• Historically, Liabilities and Shareholders Equity has averaged $877.8 million across 5 years, with a median of $826.0 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity dropped 13.48% in 2023 and soared 87.34% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $603.1 million in 2022, then declined by 4.54% to $575.8 million in 2023, then soared by 69.87% to $978.0 million in 2024, then soared by 78.2% to $1.7 billion in 2025, then dropped by 4.23% to $1.7 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.7 billion in Q1 2026, $1.7 billion in Q4 2025, and $1.1 billion in Q3 2025.